By using a genetic approach, that is, a murine model of mutant K-Ras driven lung and pancreatic cancer, it has been demonstrated that NRF2 knockout reduces tumor proliferation and increases overall survival [34], leading to a new procancer activity for NRF2. The gene discussed is KRAS; the disease is pancreatic neoplasm.